Company: MYSEW
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001213900-25-076607
Chunk: 36

Company: Myseum, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 36
---
 offered by the Company pursuant to its shelf registration statement on Form S-3 (File
No. 333-268058), which was declared effective by the Securities and Exchange Commission on December 6, 2022, a base prospectus dated December
6, 2022 and a prospectus supplement dated January 8, 2025. The closing of the sales of these securities under the Purchase Agreement took
place on January 9, 2025 and the Company received net proceeds of $4,532,000 after deducting placement fees and expenses of $568,000.
The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

Equity Sales Agreement

On February 10, 2025, the Company entered into
a Sales Agreement (the “Sales Agreement”) with The Benchmark Company, LLC (“Benchmark”) to sell shares of the
Company’s common shares (the “Shares”) having an aggregate sales price of up to $6,000,000, from time to time, through
an “at the market offering” program under which Benchmark will act as sales agent. The sales, if any, of the Shares made under
the Sales Agreement will be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule
415 promulgated under the Securities Act of 1933, as amended.

The Company will pay Benchmark a commission rate
equal to 4.0% of the aggregate gross proceeds from each sale of Shares; provided however, that in the event that the amount of Shares
sold under the Sales Agreement increases to $1 million or more, then the commission rate will be reduced to 3%. In addition, the Company
agreed to provide Benchmark with customary indemnification and contribution rights. The Company will also reimburse Benchmark for certain
specified expenses in connection with entering into the Sales Agreement. The Sales Agreement contains customary representations and warranties
and conditions to the sale of the Shares pursuant thereto. The Company is not obligated to sell any of the Shares under the Sales Agreement
and may at any time suspend solicitation and offers thereunder. The offering of Shares pursuant to the Sales Agreement will terminate
on the earlier of (1) the sale, pursuant to the Sales Agreement, of Shares having an aggregate offering price of $6,000,000 and (2) the
termination of the Sales Agreement by either us or Benchmark, as permitted therein. The Shares will be issued pursuant to our